论文部分内容阅读
IFN已成为治疗慢性丙型肝炎的主要药物,然而其治疗剂量和疗程则仍在探索中。本研究比较两种疗法的效果,A.固定剂量:IFN-α2b 3MU每周3次,持续一年;B.调整剂量:5MU每周3次给药,一月后,隔周测定ALT,一旦ALT正常则每隔一周减少1MU;减量后如ALT升高则再用IFN-α2b 5MU每周3次治疗,治疗同样持续一年。 95例慢性丙型肝炎患者,最终不用IFN-α2b治疗的对照组中有29例、固定剂量治疗组中有28例、调整剂量治疗组中有31例患者完成试验。结果显示,对照组29例中仅2例在试
IFN has become the main drug for the treatment of chronic hepatitis C, however its therapeutic dosage and course of treatment are still under investigation. This study compared the efficacy of the two therapies, A. Fixed dose: IFN-α2b 3MU 3 times a week for one year; B. Adjusted dose: 5MU administered 3 times a week, one month later, measured ALT every other week ALT is normal every other week to reduce 1MU; reduction as ALT then IFN-α2b 5MU 3 times a week treatment, the treatment lasts for another year. Of the 95 patients with chronic hepatitis C, 29 in the control group eventually did not receive IFN-α2b, 28 in the fixed-dose group, and 31 in the adjuvant-adjusted dose group. The results showed that only 29 of the 29 patients in the control group were tested